to print the meeting flyer and registration form.
Biotherapeutic Drug Research and Development:
A Growing Role for the DMPK Scientist
Dr. Jerry Galluppi, Ph.D.
Director, Pharmacokinetics, Metabolism, and Pharmacodynamics
Biogen Idec, La Jolla, CA
The presentation will describe the rapidly changing environment for biotherapeutic drug characterization and development in both the pharmaceutical industry and the regulatory sector. New guidelines for drug research and development are demanding greater mechanistic understanding of how a drug candidate functions and how this knowledge is ultimately applied to optimize therapy. The list of drug properties requiring thorough characterization is expanding and includes relatively simple measures such as potency and target selectivity to more complicated features like biodistribution of the candidate to the site of action, its tendency to induce formation of anti-drug antibodies and the impact of such antibodies on pharmacodynamics, the likelihood that the candidate will interact with concomitant medicines, how the candidate will perform in different patient populations, and many other properties which will support proof of principle in the clinic and ensure optimal use of the drug in clinical practice. All phases of research and development, from candidate discovery through clinical development and product labeling, will be considered with a special emphasis on the growing role of drug metabolism and pharmacokinetic knowledge in the development of biotherapeutic agents.
Dr. Galluppi received BS degrees in Chemistry and Biochemistry at Penn State University, a PhD in Biochemistry at Indiana University, and postdoctoral training in Molecular Biology at the University of Wisconsin. Dr. Galluppi has 30 years of experience in biotechnology and pharmaceutical research and development. He was the former Senior Research Director of Protein Biochemistry at Monsanto/Searle. He was a Clinical Pharmacology Fellow with the Center for Drug Development Science at Georgetown University, and he is also a Science Advisory Board member for several biotechnology startup companies.
||Tuesday October 5, 2010 – 5:00 p.m. (Buffet), 7:00 p.m. (Presentation)
||Johnson & Johnson Research Facility
3210 Merryfield Row
San Diego, CA 92121
$20 Registration in advance or at the door (includes buffet dinner and soft drinks)
Space is Limited — Register Early to Guarantee Your Attendance!
|Dr. Dennis Smith
|| Does drug metabolism hold its future in its own hands?
||April 27, 2010
|Dr. Paul F. Hollenberg
|| Mechanism-Based Inactivation of Human Cytochromes P450
||October 6, 2009
|Dr. Jack H. Dean
Dr. Thomas Baillie
| Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective
||May 19, 2009
|Eric Johnson, Ph.D.
|| Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography
||September 30, 2008
|Dr. Kenneth E. Thummel, Ph.D.
|| Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics
||May 7, 2008
|Dr. Anthony Lu, Ph.D.
|| Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme?
||September 12, 2007
|Dr. Scott Obach, Ph.D.
|| Leveraging ADME Data In Metabolites In Safety Testing (MIST)
||April 18, 2007
|Dr. Sidney Nelson, Ph.D.
|| Drug Metabolism and Chemical Structural Alerts
||September 27, 2006
|Richard B. Kim, MD
|| Relevance and Utility of Transporters to Drug Discovery and Development
||September 21, 2005
|Dr. Frederick P. Guengerich, Ph.D.
|| Human Cytochrome P450 2A6 as a Case History: Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450
||April 27, 2005
|Dr. Leslie Benet, Ph.D.
||Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS
||September 29, 2004
|Dr. Christopher A. Lipinski, Ph.D.
||ADME/Tox: How Low Can You Go And How Do You Recover?
||April 21, 2004
Our October 2010 meeting is generously sponsored by:
Our silver sponsors:
Bronze sponsors and meeting host: